Blood test vs. needle biopsy: can a simple draw detect lung cancer mutations?

NCT ID NCT03265496

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a blood test (liquid biopsy) could find EGFR gene mutations in lung cancer patients as accurately as a standard tumor biopsy. Researchers planned to enroll 21 patients with advanced lung cancer who had not yet received treatment. The study was terminated early, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could show that a simple blood test (liquid biopsy) can reliably detect EGFR mutations, reducing the need for invasive tumor biopsies.

What could go wrong

The study was terminated early with only 21 participants, so results are limited. The approach may not be accurate enough to replace standard tissue biopsy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHRU Lille

    Lille, 59037, France

  • Centre Oscar Lambret

    Lille, 59020, France